SCHEMBL4403557

SCHEMBL4403557

Cc1cccc[n+]1CCCC#Cc1cccc(C#CCCC[n+]2ccccc2C)c1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ CHRNA7 P36544 4/20 0.45
▸ CHRNA10 Q9GZZ6 4/20 0.45
▸ CHRNA9 Q9UGM1 4/20 0.45
▸ CHRNB2 P17787 3/20 0.36
▸ CHRNA4 P43681 3/20 0.36
▸ CHRNB4 P30926 2/20 0.36
▸ CHRNA3 P32297 2/20 0.36
▸ KCNH2 Q12809 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ GRM5 P41594 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12637954 0.94 NPC1 (0.57) NPC1POLBRAB9ASMN1; SMN2CHRNA7
SCHEMBL15694501 0.86 NPC1 (0.49) NPC1POLBRAB9ASMN1; SMN2CHRNA7
SCHEMBL4401353 0.84 CHRNA7 (0.41) NPC1POLBRAB9ASMN1; SMN2CHRNA7
SCHEMBL12638005 0.84 NPC1 (0.54) NPC1POLBRAB9ASMN1; SMN2CHRNA7
SCHEMBL4400608 0.83 SMN1; SMN2 (0.59) NPC1POLBRAB9ASMN1; SMN2CHRNA7
SCHEMBL13334175 0.83 POLB (0.51) NPC1POLBRAB9ASMN1; SMN2CHRNA7
Bromide SCHEMBL3316783 0.82 POLB (0.54) NPC1POLBRAB9ASMN1; SMN2CHRNA7
Bromide SCHEMBL16105152 0.79 NPC1 (0.50) NPC1POLBRAB9ASMN1; SMN2CHRNA7
SCHEMBL4403554 0.78 BCHE (0.58) —
SCHEMBL4398980 0.77 CHRNA7 (0.51) POLBCHRNA7CHRNA10CHRNA9CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160340335-A9 METHOD OF TREATING NEUROPATHIC PAIN UNIVERSITY OF UTAH (US) 2016-11-24 — — US disclosed
US-9499518-B2 Bis-quaternary ammonium salts as pain modulating agents UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2016-11-22 — — US disclosed
US-20160279119-A9 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2016-09-29 — — US disclosed
US-20140011836-A1 METHOD OF TREATING NEUROPATHIC PAIN UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-01-09 — — US disclosed
US-8178678-B2 Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2012-05-15 — — US disclosed
US-20110166177-A1 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-07-07 — — US disclosed
US-20100069432-A1 Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166177-A1 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS RELA, FHIT, OPRL1 NPC1 3736/4885POLB 2602/4885RAB9A 1249/4885
US-20160340335-A9 METHOD OF TREATING NEUROPATHIC PAIN INA, GAP43, ACHE NPC1 1971/4885POLB 2513/4885RAB9A 1771/4885
US-20160279119-A9 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS RELA, FHIT, OPRL1 NPC1 3736/4885POLB 2602/4885RAB9A 1249/4885
US-20100069432-A1 Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors CHRNA2, CHRNA5, CHRNA4 NPC1 1844/4885POLB 3604/4885RAB9A 920/4885
US-20140011836-A1 METHOD OF TREATING NEUROPATHIC PAIN INA, GAP43, ACHE NPC1 1971/4885POLB 2513/4885RAB9A 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback